Almost all the patients with depression who received Gilgamesh Pharmaceuticals’ psychedelic drug candidate went into remission, furthering the biotech’s attempt to follow the trail blazed by ...

Gilgamesh Pharmaceuticals’ psychedelic therapy has boasted a 94% depression remission rate after 29 days in a Phase IIa study. The trial (NCT06236880) investigated the efficacy, safety and ...

GM-2505, a novel 5-HT2A receptor agonist and 5-HT releaser, demonstrated rapid, robust, and durable antidepressant effect in MDD NEW YORK, May 27, 2025 /PRNewswire/ -- Gilgamesh Pharmaceuticals ...

These work very similarly to the bunnies in Eureka, so if you remember doing those, you’re already in a good place. You can identify these two FATEs by their unique blue icons. While they have ...

There are a few ways to unlock the various Phantom Jobs in FFXIV, which we’ve detailed below. This is the first way you’re going to unlock a chunk of the Phantom Jobs. This job serves more or ...

AbbVie has agreed to pay $65 million on an option deal with start-up Gilgamesh Pharma, lining up rights to neuroplastogen compounds that can improve neuroplasticity - the ability of the brain to ...

Image credit: Black Salmon / Shutterstock. Gilgamesh Pharmaceuticals’ psychedelic therapy has boasted a 94% depression remission rate after 29 days in a Phase IIa study. The trial (NCT06236880) ...

New York-based neurosciences company Gilgamesh Pharmaceuticals yesterday announced Phase IIa results for GM-2505, a novel, rapid-acting 5-HT2A receptor agonist and 5-HT releaser in development for the ...

NEW YORK, May 27, 2025 /PRNewswire/ -- Gilgamesh Pharmaceuticals, a clinical-stage neuroscience company developing innovative, best-in-class new chemical entities (NCEs) that transform the treatment ...

Dillon is the Senior Game Guides Editor at Fanbyte. He's been writing about video games for 15 years and has thousands of hours logged in FFXIV and hundreds of hours in Destiny 2.